Nanotechnology for COVID-19: Therapeutics and Vaccine Research
Top Cited Papers
- 22 June 2020
- journal article
- review article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 14 (7), 7760-7782
- https://doi.org/10.1021/acsnano.0c04006
Abstract
The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires an urgent deployment of advanced therapeutic options available. The role of nanotechnology is highly relevant to counter this “virus” nano enemy. Nano intervention is discussed in terms of designing effective nanocarriers to counter the conventional limitations of antiviral and biological therapeutics. This strategy directs the safe and effective delivery of available therapeutic options using engineered nanocarriers, blocking the initial interactions of viral spike glycoprotein with host cell surface receptors, and disruption of virion construction. Controlling and eliminating the spread and reoccurrence of this pandemic demands a safe and effective vaccine strategy. Nanocarriers have potential to design risk-free and effective immunization strategies for severe acute respiratory syndrome coronavirus 2 vaccine candidates such as protein constructs and nucleic acids. We discuss recent as well as ongoing nanotechnology-based therapeutic and prophylactic strategies to fight against this pandemic, outlining the key areas for nanoscientists to step in.Funding Information
- Consejo Nacional de Ciencia y Tecnolog??a (31803, 898832)
- Federico Baur Endowed Chair in Nanotechnology (0020240I03)
This publication has 270 references indexed in Scilit:
- SMART drug delivery systems: Back to the future vs. clinical realityInternational Journal of Pharmaceutics, 2013
- Nanoparticle Hydrophobicity Dictates Immune ResponseJournal of the American Chemical Society, 2012
- Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trialThe Lancet Infectious Diseases, 2011
- Programming the magnitude and persistence of antibody responses with innate immunityNature, 2011
- Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer TherapyMolecular Therapy, 2010
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacyVaccine, 2009
- Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilizationNature Immunology, 2008
- Pathogen Recognition and Innate ImmunityCell, 2006
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004